sbi-0206965 and olaparib
sbi-0206965 has been researched along with olaparib* in 1 studies
Other Studies
1 other study(ies) available for sbi-0206965 and olaparib
| Article | Year |
|---|---|
Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein-1 Homolog; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Drug Synergism; Female; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Mice, Inbred C57BL; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Triple Negative Breast Neoplasms | 2020 |